ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0078

Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems

Alexis Ogdie1, Marina Magrey2, Robert Fitzsimmons3, Shahrzad Abdollahi4, Wai Chung Yong5, Yasir Tarabichi6, Ana Biljan7, Christopher D. Saffore7, Kristin Tacelosky7 and Jessica Walsh8, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Case Western Reserve University, University Hospitals, Richfield, OH, 3Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4Division of Rheumatology, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA, 5Division of Rheumatology, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, 6Department of Clinical Informatics Research and Education, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, 7AbbVie, Inc., North Chicago, IL, 8University of Utah, Salt Lake City, UT

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), Health Care, primary care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Most patients with undiagnosed ankylosing spondylitis (AS) seek care for back pain from primary care providers (PCPs), and treatment strategies adopted by PCPs may vary from those used by rheumatologists.1 The objective of this analysis was to examine the prescribing habits of rheumatologists and PCPs who were treating patients with AS.

Methods: A retrospective cross-sectional study was performed using electronic medical records from the health systems of the University of Pennsylvania (UPENN), the University of Utah (Utah), and from MetroHealth. Patients who were diagnosed with AS (International Classification of Diseases, 10th Revision code M45.X or M08.1) between January 2017 and September 2020 were included. Baseline characteristics at the time of first diagnosis code, visits to rheumatologists and PCPs, and prescribed therapies are reported descriptively.

Results: In total, 2,395 patients with a qualifying diagnosis code were identified: UPENN, n=1,271; MetroHealth, n=182; Utah, n=942. The mean age of patients was 51 years in UPENN and MetroHealth systems, and 44 years in the Utah system; 55%, 48%, and 48% of patients in the UPENN, MetroHealth and Utah systems, respectively, were male (Table 1). Common comorbidities included anemia, anxiety, depression, hyperlipidemia, and hypertension, although prevalence differed by health system. In contrast, the prevalence of inflammatory bowel disease, uveitis, and psoriasis were generally consistent across the three health systems. The proportions of patients who were seen by a rheumatologist, a PCP, or both, also differed by health system (Figure 1). Across all institutions, patients followed by a rheumatologist were far more likely to receive biologic DMARD (bDMARD) prescriptions than those followed by a PCP alone (Figure 2). Overall, conventional synthetic DMARDs (csDMARDs) were prescribed less frequently than bDMARDs and were not commonly prescribed to patients who were followed up by PCPs alone. Both opiate and non-opiate pain medications were commonly used and were most frequently prescribed to patients, followed up by PCPs alone.

Conclusion: In this population of patients with AS followed in three different health systems, bDMARDs and csDMARDs were more frequently prescribed to patients seen by a rheumatologist than to patients seen by a PCP alone. By contrast, opiate and non-opiate pain medications were prescribed more frequently to patients who were followed up by a PCP alone. These findings from multiple institutions demonstrate the variability in prescribing patterns between PCPs and rheumatologists and highlight areas for targeted education of clinicians caring for patients with AS.

Reference 1.Deodhar A, et al. Clin Rheumatol 2016;35:1769–76

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Ogdie, AbbVie, Amgen, Novartis, Pfizer Inc, Bristol-Myers Squibb, Celgene, Janssen, CorEvitas, Gilead Sciences, Eli Lilly, GlaxoSmithKline, Happify Health, UCB; M. Magrey, AbbVie, Eli Lilly, Novartis, Pfizer Inc, UCB; R. Fitzsimmons, None; S. Abdollahi, None; W. Yong, None; Y. Tarabichi, None; A. Biljan, AbbVie; C. Saffore, AbbVie; K. Tacelosky, AbbVie; J. Walsh, AbbVie, Amgen, Lilly, Novartis, Pfizer, UCB, Celgene, Janssen, Merck.

To cite this abstract in AMA style:

Ogdie A, Magrey M, Fitzsimmons R, Abdollahi S, Yong W, Tarabichi Y, Biljan A, Saffore C, Tacelosky K, Walsh J. Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/treatment-of-ankylosing-spondylitis-by-primary-care-physicians-and-rheumatologists-a-retrospective-study-in-three-health-systems/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-ankylosing-spondylitis-by-primary-care-physicians-and-rheumatologists-a-retrospective-study-in-three-health-systems/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology